Skip Navigation


Carcinogenesis Advance Access originally published online on March 2, 2006
Carcinogenesis 2006 27(8):1538-1546; doi:10.1093/carcin/bgl002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
27/8/1538    most recent
bgl002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Lin, X.
Right arrow Articles by Tonetti, D. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lin, X.
Right arrow Articles by Tonetti, D. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Overexpression of PKC{alpha} is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model

Xin Lin, Yanni Yu, Huiping Zhao, Yiyun Zhang, Jessica Manela1 and Debra A. Tonetti*

Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago Chicago, IL, USA
1 Robert H. Lurie Comprehensive Cancer Center, Northwestern University Chicago, IL, USA

*To whom correspondence should be addressed at: Department of Biopharmaceutical Sciences, College of Pharmacy, University of Illinois at Chicago, 833 S Wood Street (M/C 865), Chicago, IL 60612, USA. Tel: +1 312 413 1169; Fax: +1 312 996 1698; Email: dtonetti{at}uic.edu

We previously reported that stable overexpression of protein kinase C alpha (PKC{alpha}) in hormone responsive T47D:A18 breast cancer cells produces a hormone-independent/tamoxifen (TAM)-resistant and 17ß-estradiol (E2)-inhibitory phenotype in vivo. Furthermore, overexpression of PKC{alpha} in T47D:A18 cells also results in cross-upregulation of PKCs ß and {delta}. In this study, we further characterized the contribution of PKC isozymes {alpha}, ß and {delta} to this complex phenotype. To determine whether downregulation of PKC{alpha} is sufficient to restore the hormone-dependent phenotype in T47D:A18/PKC{alpha} cells, PKC{alpha} was selectively knocked down using short hairpin RNA (shRNA). To determine the contribution of PKCß or {delta} to the hormone-independent/TAM-resistant and E2-inhibitory phenotype, stable T47D:A18/PKCß and T47D:A18/PKC{delta} clones were established. Downregulation of PKC{alpha} by shRNA in T47D:A18/PKC{alpha}20 cells also resulted in reduced PKCß protein expression in vitro. Tumors established from a T47D:A18/PKC{alpha}/shRNA stable clone exhibit 50% reduction of PKC{alpha} protein without concomitant reduction in PKCß, and exhibit partial reversal of the TAM-resistant and E2-inhibitory phenotype in vivo. Furthermore, stable overexpression of neither PKCß nor PKC{delta} in T47D:A18 cells are sufficient to produce hormone-independent growth in vitro or in vivo, nor TAM-resistant and E2-inhibited growth in vivo. Taken together, these results suggest that PKC{alpha} is required to impart the TAM-resistant and E2-inhibitory phenotype in vivo.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Pathol.Home page
J W Assender, J M W Gee, I Lewis, I O Ellis, J F R Robertson, and R I Nicholson
Protein kinase C isoform expression as a predictor of disease outcome on endocrine therapy in breast cancer
J. Clin. Pathol., November 1, 2007; 60(11): 1216 - 1221.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.